Research ArticleClinical Investigations
Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer
Steven P. Rowe, Katarzyna J. Macura, Anthony Ciarallo, Esther Mena, Amanda Blackford, Rosa Nadal, Emmanuel S. Antonarakis, Mario A. Eisenberger, Michael A. Carducci, Ashley E. Ross, Philip W. Kantoff, Daniel P. Holt, Robert F. Dannals, Ronnie C. Mease, Martin G. Pomper and Steve Y. Cho
Journal of Nuclear Medicine January 2016, 57 (1) 46-53; DOI: https://doi.org/10.2967/jnumed.115.163782
Steven P. Rowe
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland
Katarzyna J. Macura
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland
2Department of Medical Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland
3The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland; and
Anthony Ciarallo
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland
Esther Mena
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland
Amanda Blackford
2Department of Medical Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland
Rosa Nadal
2Department of Medical Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland
Emmanuel S. Antonarakis
2Department of Medical Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland
Mario A. Eisenberger
2Department of Medical Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland
Michael A. Carducci
2Department of Medical Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland
Ashley E. Ross
3The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland; and
Philip W. Kantoff
4Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
Daniel P. Holt
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland
Robert F. Dannals
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland
Ronnie C. Mease
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland
Martin G. Pomper
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland
Steve Y. Cho
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 1
January 1, 2016
Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer
Steven P. Rowe, Katarzyna J. Macura, Anthony Ciarallo, Esther Mena, Amanda Blackford, Rosa Nadal, Emmanuel S. Antonarakis, Mario A. Eisenberger, Michael A. Carducci, Ashley E. Ross, Philip W. Kantoff, Daniel P. Holt, Robert F. Dannals, Ronnie C. Mease, Martin G. Pomper, Steve Y. Cho
Journal of Nuclear Medicine Jan 2016, 57 (1) 46-53; DOI: 10.2967/jnumed.115.163782
Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer
Steven P. Rowe, Katarzyna J. Macura, Anthony Ciarallo, Esther Mena, Amanda Blackford, Rosa Nadal, Emmanuel S. Antonarakis, Mario A. Eisenberger, Michael A. Carducci, Ashley E. Ross, Philip W. Kantoff, Daniel P. Holt, Robert F. Dannals, Ronnie C. Mease, Martin G. Pomper, Steve Y. Cho
Journal of Nuclear Medicine Jan 2016, 57 (1) 46-53; DOI: 10.2967/jnumed.115.163782
Jump to section
Related Articles
Cited By...
- Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy
- The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
- 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy
- Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer
- Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories
- A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer
- Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging
- Anatomic and Molecular Imaging in Prostate Cancer
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- PSMA Ligands for PET Imaging of Prostate Cancer
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
- Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake
- Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
- (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted {alpha}-Particle Radiopharmaceutical Therapy
- Evaluation of Prostate Cancer with PET/MRI
- Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer